Investigation of Circulating MicroRNA Levels in Antibody-Mediated Rejection After Kidney Transplantation

被引:1
|
作者
Nagy, Peter Ferenc [1 ]
Pocsi, Marianna [2 ]
Fejes, Zsolt [2 ]
Bidiga, Laszlo [3 ]
Szabo, Eszter [1 ]
Balogh, Orsolya [1 ]
Szollosi, Gergo Jozsef [4 ]
Nagy, Bela, Jr. [2 ]
Nemes, Balazs [1 ]
机构
[1] Univ Debrecen, Fac Med, Inst Surg, Dept Organ Transplantat, Debrecen, Hungary
[2] Univ Debrecen, Fac Med, Dept Lab Med, Debrecen, Hungary
[3] Univ Debrecen, Fac Med, Dept Pathol, Debrecen, Hungary
[4] Univ Debrecen, Fac Publ Hlth, Dept Intervent Epidemiol, Debrecen, Hungary
关键词
EXPRESSION;
D O I
10.1016/j.transproceed.2022.10.044
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. One of the most important possible complications determining long-term graft survival after kidney transplant is antibody-mediated rejection (ABMR). The criterion standard approach to recognize ABMR is currently the kidney biopsy with histopathologic analysis. However, this test has limitations because of difficulties in timing of sampling, the evaluability of histology because of the questionable representativeness of specimens, and the limited number of this intervention. Hence, new reliable, noninvasive biomarkers are required to detect the development of ABMR in time. Methods. In this study, we analyzed the clinical data of 45 kidney transplant patients (mean age of 44.51 years, 20 male and 25 female subjects). These participants were recruited into 5 subcohorts based on their clinical status, histologic findings, and level of donor-specific anti-HLA antibodies. Circulating microRNAs (miR-21, miR-181b, miR-146a, miR-223, miR-155, miR-150) in plasma samples were quantified by quantitative polymerase chain reaction and their levels were correlated with the clinical characteristics in different subgroups. Results. The relative expression of plasma miR-155 (P = .0003), miR-223 (P = .0316), and miR-21 (P = .0147) were significantly higher in patients who had subsequent histology-approved ABMR with donor-specific anti-HLA antibody positivity (n = 10) than in the "triple negative" group (n = 21), and miR-155 showed the highest sensitivity (90%) and specificity (81%) to indi-cate ABMR development based on receiver operating characteristic analysis. Conclusions. According to our preliminary data, plasma miR-155, miR-21, and miR-223 can indicate the development of ABMR after kidney transplant in correlation with classic clinical parameters. However, future studies with larger number of participants are necessary to further evaluate the diagnostic properties of blood miRNAs in prediction of this life-threatening condition.
引用
收藏
页码:2570 / 2577
页数:8
相关论文
共 50 条
  • [1] Treatment of antibody-mediated rejection after kidney transplantation
    Sureshkurnar, K. K.
    Oti, I. U.
    Baroody, S. C.
    Hussain, S. M.
    Carpenter, B. J.
    Nghiem, D. D.
    Marcus, R. J.
    TRANSPLANTATION PROCEEDINGS, 2008, 40 (05) : 1373 - 1374
  • [2] ASSOCIATION BETWEEN TACROLIMUS LEVELS AND ANTIBODY-MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION
    Ruiz-Esteban, Pedro yyy
    Gonzalez-Molina, Miguel
    Caballero, Abelardo
    Palma, Eulalia
    Burgos, Dolores
    Cabello, Mercedes
    Alonso-Titos, Juana
    Duarte, Ana
    Hernandez, Domingo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 316 - 316
  • [3] Urinary Exosomal MicroRNA Biomarkers for Antibody-Mediated Rejection After Kidney Transplantation.
    Shin, S.
    Kim, M.
    Lim, S.
    Kwon, H.
    Jung, J.
    Ko, Y.
    Kwon, H.
    Kim, Y.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 916 - 916
  • [4] Late Antibody-Mediated Rejection (AMR) after Kidney Transplantation
    Martina, M.
    Oppenheimer, F.
    Revuelta, I.
    Campistol Planas, J.
    Sole, M.
    Cid, J.
    Diekmann, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 325 - 325
  • [5] The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation
    Lee, Juhan
    Kim, Beom Seok
    Park, Yongjung
    Lee, Jae Geun
    Lim, Beom Jin
    Jeong, Hyeon Joo
    Kim, Yu Seun
    Huh, Kyu Ha
    YONSEI MEDICAL JOURNAL, 2015, 56 (06) : 1638 - 1642
  • [6] A Monocyte-Derived MicroRNA Signature for Antibody-Mediated Rejection in Kidney Transplantation
    Tinel, C.
    Lamarthee, B.
    Von Tokarski, F.
    Rabant, M.
    Legendre, C.
    Gwinner, W.
    Naesens, M.
    Marquet, P.
    Anglicheau, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 309 - 310
  • [7] Antibody-mediated rejection in kidney transplantation: an update
    Lucas, Jessica G.
    Co, Jeannie P.
    Nwaogwugwu, Uzoamaka T.
    Dosani, Imran
    Sureshkumar, Kalathil K.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (04) : 579 - 592
  • [8] Comparison of Clinical Characteristics and Outcomes of Early Antibody-Mediated Rejection and Late Antibody-Mediated Rejection after Kidney Transplantation
    Chen, G.
    Wu, Z.
    Wang, C.
    Liu, X.
    Li, Q.
    Chen, L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 846 - 846
  • [9] Treatment of antibody-mediated rejection in kidney transplantation
    Venetz, Jean-Pierre
    Pascual, Manuel
    EJHP PRACTICE, 2008, 14 (05): : 21 - 24
  • [10] Antibody-Mediated Rejection in Kidney Transplantation: A Review
    Puttarajappa, Chethan
    Shapiro, Ron
    Tan, Henkie P.
    JOURNAL OF TRANSPLANTATION, 2012, 2012